{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:49:05Z","timestamp":1791568145674,"version":"4.3.4"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Psilocybin has demonstrated rapid and sustained antidepressant efficacy, with acute-phase effect sizes often more than double those for conventional antidepressants. However, concerns have been raised that high rates of functional unblinding in combination with trial participants with positive expectations of psychedelic use might bias treatment outcomes.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare outcomes for patients receiving control treatments in randomized clinical trials of psilocybin for depression with control treatment outcomes from trials of selective serotonin reuptake inhibitors (SSRIs) and esketamine.<\/jats:p>\n <\/jats:sec>\n \n Data Sources<\/jats:title>\n Two previous meta-analyses and 1 US Food and Drug Administration review published between March 2019 and December 2024 were used to identify double-blind trials on adult major depressive disorder (MDD) or treatment-resistant depression (TRD) that had a relevant control treatment arm and used the Montgomery-\u00c5sberg Depression Rating Scale (MADRS) for symptom rating.<\/jats:p>\n <\/jats:sec>\n \n Study Selection<\/jats:title>\n Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guideline, trials of psilocybin for MDD and TRD, esketamine for TRD, and a selective serotonin reuptake inhibitor (SSRI) for MDD were selected. Studies that included only individuals aged younger than 18 years or older than 65 years, used a crossover design, or had a duration less than 2 weeks were excluded.<\/jats:p>\n <\/jats:sec>\n \n Data Extraction and Synthesis<\/jats:title>\n All authors assessed the 3 reviews for includable trials. Three authors independently extracted data for all trials, with disagreements resolved by consensus discussion. Data were pooled using random-effects models.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Standardized mean change (SMC) in MADRS scores from baseline to up to 6 weeks after randomization was used to assess within-group effect sizes, and standardized mean difference (SMD) was used to assess between-group effect sizes. Omnibus Test of Moderators (QM) was used to test whether the study population significantly moderated effect sizes.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The study included 17 trials: 4 of psilocybin (n\u2009=\u2009373), 2 of esketamine (n\u2009=\u2009573), and 11 of SSRIs (n\u2009=\u20094014). Pretreatment to posttreatment SMCs (SEMs) were 1.21 (0.15) for psilocybin, 1.28 (0.06) for SSRIs, and 1.43 (0.15) for esketamine and were 0.50 (0.15), 1.00 (0.08), and 1.12 (0.17) for their respective control treatments. Study population was a significant moderator of between-group SMDs (QM, 10.7;\n df<\/jats:italic>\n , 2;\n P<\/jats:italic>\n \u2009=\u2009.005) and pre\u2013 to post\u2013control treatment SMCs (QM, 10.4;\n df<\/jats:italic>\n , 2;\n P<\/jats:italic>\n \u2009=\u2009.005) but not of pre\u2013 to post\u2013active treatment SMCs (QM, 1.21;\n df<\/jats:italic>\n , 2;\n P<\/jats:italic>\n \u2009=\u2009.55). MADRS response rates for control treatments in SSRI trials were 14 percentage points higher than in psilocybin trials and in esketamine trials were 23 percentage points higher than in psilocybin trials. Dropout rates for psilocybin (active treatment: 10 of 186 [5%]; control: 20 of 187 [11%]) and esketamine (active treatment: 43 of 349 [12%]; control: 18 of 224 [8%]) were similar and considerably lower than for SSRIs (active treatment: 866 of 2694 [32%]; control: 467 of 1320 [35%]).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this meta-analysis of control treatment outcomes in trials of psilocybin, SSRIs, or esketamine for depression, participants receiving control treatment in psilocybin trials had significantly less improvement in depression ratings than participants receiving control treatment in trials of SSRIs or esketamine. This might indicate that psilocybin\u2019s antidepressant efficacy is overestimated compared with that of SSRIs and esketamine.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.24119","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:31:11Z","timestamp":1753889471000},"page":"e2524119","source":"Crossref","is-referenced-by-count":30,"title":["Control Group Outcomes in Trials of Psilocybin, SSRIs, or Esketamine for Depression"],"prefix":"10.1001","volume":"8","author":[{"given":"Fredrik","family":"Hieronymus","sequence":"first","affiliation":[{"name":"Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden"},{"name":"Department of Affective Disorders, Aarhus University, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evana","family":"L\u00f3pez","sequence":"additional","affiliation":[{"name":"Centre for Psychiatry Research, Karolinska Institute & Stockholm Health Care Services, Region Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Werin Sj\u00f6gren","sequence":"additional","affiliation":[{"name":"Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden"},{"name":"Sahlgrenska University Hospital, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Lundberg","sequence":"additional","affiliation":[{"name":"Centre for Psychiatry Research, Karolinska Institute & Stockholm Health Care Services, Region Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"issue":"2","key":"zoi250687r1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050045","article-title":"Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration.","volume":"5","author":"Kirsch","year":"2008","journal-title":"PLoS Med"},{"issue":"9","key":"zoi250687r2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.25531","article-title":"Magnitude of the placebo response across treatment modalities used for treatment-resistant depression in adults: a systematic review and meta-analysis.","volume":"4","author":"Jones","year":"2021","journal-title":"JAMA Netw Open"},{"key":"zoi250687r3","doi-asserted-by":"publisher","DOI":"10.1017\/S2045796024000611","article-title":"The overestimation of the effect sizes of psychotherapies for depression in waitlist controlled trials: a meta-analytic comparison with usual care controlled trials.","volume":"33","author":"Cuijpers","year":"2024","journal-title":"Epidemiol Psychiatr Sci"},{"key":"zoi250687r4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078084","article-title":"Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis.","volume":"385","author":"Metaxa","year":"2024","journal-title":"BMJ"},{"issue":"9","key":"zoi250687r5","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2023.14530","article-title":"Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial.","volume":"330","author":"Raison","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"zoi250687r6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1089\/psymed.2023.0028","article-title":"A systematic review of study design and placebo controls in psychedelic research.","volume":"2","author":"Wen","year":"2024","journal-title":"Psychedelic Med (New Rochelle)"},{"issue":"3","key":"zoi250687r7","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1001\/jamapsychiatry.2024.4312","article-title":"Modifying informed consent to help address functional unmasking in psychedelic clinical trials.","volume":"82","author":"Matvey","year":"2025","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"zoi250687r8","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12916-024-03322-1","article-title":"Low awareness of the transitivity assumption in complex networks of interventions: a systematic survey from 721 network meta-analyses.","volume":"22","author":"Spineli","year":"2024","journal-title":"BMC Med"},{"issue":"2","key":"zoi250687r9","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1177\/00048674241289024","article-title":"The safety of psilocybin-assisted psychotherapy: a systematic review.","volume":"59","author":"Freitas","year":"2025","journal-title":"Aust N Z J Psychiatry"},{"issue":"3","key":"zoi250687r11","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/wps.21029","article-title":"The response pattern to SSRIs as assessed by the Montgomery-\u00c5sberg Depression Rating Scale: a patient-level meta-analysis.","volume":"21","author":"Hieronymus","year":"2022","journal-title":"World Psychiatry"},{"key":"zoi250687r12","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/j.2044-8317.1988.tb00901.x","article-title":"Synthesizing standardized mean-change measures.","volume":"41","author":"Becker","year":"1988","journal-title":"Br J Math Stat Psychol"},{"issue":"3","key":"zoi250687r13","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/acps.13340","article-title":"Determining maximal achievable effect sizes of antidepressant therapies in placebo-controlled trials.","volume":"144","author":"Hieronymus","year":"2021","journal-title":"Acta Psychiatr Scand"},{"issue":"15","key":"zoi250687r14","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression.","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N Engl J Med"},{"key":"zoi250687r15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101809","article-title":"Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial.","volume":"56","author":"von Rotz","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"18","key":"zoi250687r16","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression.","volume":"387","author":"Goodwin","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi250687r17","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/ijnp\/pyz039","article-title":"Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1).","volume":"22","author":"Fedgchin","year":"2019","journal-title":"Int J Neuropsychopharmacol"},{"issue":"6","key":"zoi250687r18","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study.","volume":"176","author":"Popova","year":"2019","journal-title":"Am J Psychiatry"},{"issue":"5","key":"zoi250687r20","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/j.1600-0447.1993.tb03376.x","article-title":"A comparison of paroxetine and placebo in depressed outpatients.","volume":"87","author":"Dunbar","year":"1993","journal-title":"Acta Psychiatr Scand"},{"issue":"2","key":"zoi250687r21","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/0165-0327(93)90035-I","article-title":"A study comparing paroxetine placebo and imipramine in depressed patients.","volume":"28","author":"Feighner","year":"1993","journal-title":"J Affect Disord"},{"key":"zoi250687r22","first-page":"21","article-title":"Optimal dose regimen for paroxetine.","volume":"53","author":"Dunner","year":"1992","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"zoi250687r24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/00004850-199400920-00005","article-title":"A double-blind, placebo-controlled comparison of sertraline and dothiepin in the treatment of major depression in general practice.","volume":"9","author":"Doogan","year":"1994","journal-title":"Int Clin Psychopharmacol"},{"key":"zoi250687r25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/00004850-199206005-00007","article-title":"Dose response relationship of citalopram 20 mg, citalopram 40 mg and placebo in the treatment of moderate and severe depression.","volume":"6","author":"Montgomery","year":"1992","journal-title":"Int Clin Psychopharmacol"},{"issue":"12","key":"zoi250687r27","doi-asserted-by":"publisher","first-page":"824","DOI":"10.4088\/JCP.v60n1204","article-title":"Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression.","volume":"60","author":"Feighner","year":"1999","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"zoi250687r28","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/00004850-200205000-00001","article-title":"Escitalopram 10 mg\/day is effective and well tolerated in a placebo-controlled study in depression in primary care.","volume":"17","author":"Wade","year":"2002","journal-title":"Int Clin Psychopharmacol"},{"issue":"4","key":"zoi250687r29","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/01.yic.0000074988.54339.7c","article-title":"Escitalopram (10-20 mg\/day) is effective and well tolerated in a placebo-controlled study in depression in primary care.","volume":"18","author":"Lepola","year":"2003","journal-title":"Int Clin Psychopharmacol"},{"issue":"5","key":"zoi250687r30","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1097\/JCP.0000000000001465","article-title":"Esketamine nasal spray for the rapid reduction of depressive symptoms in major depressive disorder with acute suicidal ideation or behavior.","volume":"41","author":"Canuso","year":"2021","journal-title":"J Clin Psychopharmacol"},{"issue":"7","key":"zoi250687r31","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1176\/appi.ajp.2018.17060720","article-title":"Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study.","volume":"175","author":"Canuso","year":"2018","journal-title":"Am J Psychiatry"},{"issue":"13","key":"zoi250687r32","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1038\/npp.2012.153","article-title":"A meta-analysis of factors impacting detection of antidepressant efficacy in clinical trials: the importance of academic sites.","volume":"37","author":"Dunlop","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"zoi250687r33","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-024886","article-title":"Considering the methodological limitations in the evidence base of antidepressants for depression: a reanalysis of a network meta-analysis.","volume":"9","author":"Munkholm","year":"2019","journal-title":"BMJ Open"},{"key":"zoi250687r34","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2019.109777","article-title":"Meta-analysis of placebo group dropout in adult antidepressant trials.","volume":"98","author":"Li","year":"2020","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"1","key":"zoi250687r35","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jad.2012.01.031","article-title":"Does differential drop-out explain the influence of study design on antidepressant response? a meta-analysis.","volume":"140","author":"Rutherford","year":"2012","journal-title":"J Affect Disord"},{"issue":"10128","key":"zoi250687r36","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"key":"zoi250687r10","unstructured":"Center for Drug Evaluation and Research, US Food and Drug Administration. Application number 211243Orig1s000: clinical review\u2014Spravato (esketamine). March 5, 2019. Accessed May 28, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/211243Orig1s000MedR.pdf"},{"key":"zoi250687r19","unstructured":"A phase II, placebo-controlled, double-blind study of paroxetine in depressed outpatients. GlaxoSmithKline Study Register. Updated November 4, 2018. Accessed June 19, 2025. https:\/\/www.gsk-studyregister.com\/en\/trial-details\/?id=29060\/01\/001"},{"key":"zoi250687r23","unstructured":"A double-blind, placebo-controlled, fixed-dosage study comparing the efficacy and tolerability of paroxetine CR and citalopram to placebo in the treatment of major depressive disorder with anxiety. GlaxoSmithKline Study Register. Updated November 7, 2018. Accessed June 19, 2025. https:\/\/www.gsk-studyregister.com\/en\/trial-details\/?id=29060\/785"},{"key":"zoi250687r26","unstructured":"US Food and Drug Administration. Drug approval package\u2014Celexa tablets (citalopram hydrobromide). July 17, 1998. Accessed June 19, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/98\/020822a.cfm"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2836921\/hieronymus_2025_oi_250687_1757089119.87801.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T15:00:35Z","timestamp":1757602835000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2836921"}},"subtitle":["A Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.24119","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]}}}